AMD3100
information and resources from the National Cancer Institute
AMD3100
A bicyclam with hematopoietic stem cell-mobilizing properties. AMD3100 blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.
|
|
|
|
news articles
Drug duo: New hope in cancer fight Dec 18, 2005
Macon Telegraph, The experimental therapy McGuirk and other doctors are trying combines Neupogen with another drug, AMD3100, that dislodges stem cells from their home in the ...
Anormed Announces 73% of Cancer Patients Who Failed Prior ... Dec 12, 2005
DG News VANCOUVER, CANADA -- December 12, 2005 -- AnorMED announces the first report of clinical results on Mozobil (AMD3100), a first in class stem cell mobilizer ...
AnorMED announces 73 percent of cancer patients who failed prior ... Dec 12, 2005
PR Newswire (press release), 12 /PRNewswire-FirstCall/ - AnorMED (AMEX: AOM, TSX:AOM) announces the first report of clinical results on MOZOBIL (AMD3100), a first in class stem cell ...
AnorMED Announces 73 Percent of Cancer Patients who Failed Prior ... Dec 12, 2005
PharmaLive.com (press release), VANCOUVER, British Columbia, December 12, 2005 /PRNewswire-FirstCall/ - AnorMED announces the first report of clinical results on MOZOBIL (AMD3100), a first in ...
Drug duo: New hope in cancer fight Dec 18, 2005
Macon Telegraph, The experimental therapy McGuirk and other doctors are trying combines Neupogen with another drug, AMD3100, that dislodges stem cells from their home in the ...
Anormed Announces 73% of Cancer Patients Who Failed Prior ... Dec 12, 2005
DG News VANCOUVER, CANADA -- December 12, 2005 -- AnorMED announces the first report of clinical results on Mozobil (AMD3100), a first in class stem cell mobilizer ...
AnorMED announces 73 percent of cancer patients who failed prior ... Dec 12, 2005
PR Newswire (press release), 12 /PRNewswire-FirstCall/ - AnorMED (AMEX: AOM, TSX:AOM) announces the first report of clinical results on MOZOBIL (AMD3100), a first in class stem cell ...
AnorMED Announces 73 Percent of Cancer Patients who Failed Prior ... Dec 12, 2005
PharmaLive.com (press release), VANCOUVER, British Columbia, December 12, 2005 /PRNewswire-FirstCall/ - AnorMED announces the first report of clinical results on MOZOBIL (AMD3100), a first in ...
|
|
